Observing cancer cases in the Sud-Provence-Alpes-Côte d'Azur region
Official title: Population-based Cancer Observatory of the French Region Sud-Provence-Alpes-Côte d'Azur Recruiting Incident Cases of Cancer Since 2005
Run by Centre Hospitalier Universitaire de Nice · NCT03687151 · Data updated 2026-11-12
This study is setting up a cancer tracking system in the Sud-Provence-Alpes-Côte d'Azur region to gather important information about cancer cases to help improve prevention and treatment strategies.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Nice Academic / other |
| Locations | 1 site (Nice) |
| Status | Recruiting |
| Started | January 1, 2005 |
| Main results expected | December 31, 2050 |
| Study ends | December 31, 2050 |
| Registry record updated | September 27, 2018 |
| Trial ID | NCT03687151 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals diagnosed with invasive or in situ cancer residing in the Sud-Provence-Alpes-Côte d'Azur region.
✕Probably not a fit
Patients without a cancer diagnosis or those living outside the Sud-Provence-Alpes-Côte d'Azur region may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to establish a Cancer Observatory in the Sud-Provence-Alpes-Côte d'Azur region of France, where there is currently no cancer registry. The initiative is led by the public health department of Nice Côte d'Azur University and focuses on collecting comprehensive data on invasive and in situ cancers from histopathology labs. The goal is to evaluate the effectiveness of cancer control policies and improve prevention and management strategies through reliable data collection for epidemiological research.
Why it matters
Potential benefit: If successful, this initiative could enhance cancer prevention and management strategies in the region, ultimately improving patient outcomes.
How similar studies have gone: While similar cancer registries have been successful in other regions, this specific approach to establishing a Cancer Observatory in this area is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All subjects with a diagnosis of invasive or in situ cancer living in the French Region Sud-Provence-Alpes-Côte d'Azur. Exclusion Criteria: \-
Where it's running
-
Nice University Hospital
Nice, France Recruiting
Study contacts
- Study coordinator: eugenia MARINE BARJOAN, PH
- Email: marine-barjoan.e@chu-nice.fr
- Phone: 33492035635
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.